Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus

Infection and Immunity

Volumn 64, Issue 6, 1996, Pages 2220-2224

  Devi, Sarvamangala J N ^a   Hayat, Unaiza ^b   Powell, Jan L ^b   Morris Jr , J Glenn ^b,c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b University of Maryland School of Medicine Center for Vaccine Development   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; FREUND ADJUVANT; TETANUS TOXOID;

ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTICEMIA; VIBRIO VULNIFICUS;

EID: 0029901602     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.6.2220-2224.1996     Document Type: Article

References (40)

1. Bahrani, K., and J. D. Oliver. 1990. Studies on the lipopolysaccharide of a virulent and an avirulent strain of Vibrio vulnificus. Biochem. Cell Biol. 68:547-551.
2. Carruthers, M. M., and W. J. Kabat. 1981. Vibrio vulnificus (lactose-positive vibrio) and Vibrio parahaemolyticus differ in their suceptibilities to human serum. Infect. Immun. 32:964-966.
3. Chin, K. P., M. A. Lowe, M. J. Tong, and A. L. Koehler. 1987. Vibrio vulnificus infection after raw oyster ingestion in a patient with liver disease and acquired immune deficiency syndrome-related complex. Gastroenterology 92:796-799.
4. Chuang, Y.-C., C.-Y. Yuan, C.-Y. Liu, C-K. Lan, and A. H.-M. Huang. 1992. Vibrio vulnificus infections in Taiwan: report of 28 cases and review of clinical manifestations and treatment. Clin. Infect. Dis. 15:271-276.
5. Devi, S. J. N., A. B. Karpas, and C. E. Frasch. Binding diversity of monoclonal antibodies to α(2→8) polysialic acid conjugated to outer membrane vesicle via adipic acid dihydrazide. FEMS Immunol. Med. Microbiol., in press.
6. Devi, S. J. N., U. Hayat, C. E. Frasch, A. S. Kreger, and J. G. Morris, Jr. 1995. Capsular polysaccharide-protein conjugate vaccines of carbotype 1 Vibrio vulnificus: construction, immunogenicity, and protective efficacy in a murine model. Infect. Immun. 63:2906-2911.
7. Foire, A., U. Hayat, S. S. Wasserman, A. C. Wright, and J. G. Morris, Jr. Antibodies which react with the capsular polysaccharide of Vibrio vulnificus are detectable in infected patients, and in persons without known exposure to the organism. Diagn. Microbiol. Infect. Dis., in press.
8. Gray, L. D., and A. S. Kreger. 1987. Mouse skin damage caused by cytolysin from Vibrio vulnificus and by V. vulnificus infection. J. Infect. Dis. 155:236-241.
9. Hayat, U., G. P. Reddy, C. A. Bush, J. A. Johnson, A. C. Wright, and J. G. Morris, Jr. 1993. Capsular types of Vibrio vulnificus. An analysis of strains from clinical and environmental sources. J. Infect. Dis. 168:758-762.
10. Hoge, C. W., D. Watsky, R. N. Peeler, J. P. Libonati, E. Israel, and J. G. Morris, Jr. 1989. Epidemiology and spectrum of Vibrio infections in a Chesapeake Bay community. J. Infect. Dis. 160:985-993.
11. Johnson, D. E., F. M. Calia, D. M. Musher, and A. Goree. 1984. Resistance of Vibrio vulnificus to serum and opsonizing factors: relation to virulence in suckling mice and humans. J. Infect. Dis. 150:413-418.
12. Johnsion, J. M., S. F. Becker, and L. M. McFarland. 1985. ViMo vulnificus: man and the sea. JAMA 253:2850-2853.
13. Kikawa, K., K. Yamasaki, T. Sujiura, H. Myose, M. Chilien, K. Tsutsumi, N. Iwao, and T. Dohzono. 1990. A successfully treated case of Vibrio vulnificus septicaemia with shock. Jpn. J. Med. 29:313-319.
14. Klontz, K. C., S. Leib, M. Schreiber, H. T. Janowski, L. M. Baldy, and R. A. Gunn. 1988. Syndromes of Vibrio vulnificus infections: clinical and epidemiologic features in Florida cases, 1981-1987. Ann. Intern. Med. 109:318-323.
15. Koenig, K. L., J. Mueller, and T. Rose. 1991. Vibrio vulnificus: hazard on the half shell. West. J. Med. 155:400-403.
16. Kothary, M. A., and A. S. Kreger. 1985. Production and partial characterization of an elastolytic protease of Vibrio vulnificus. Infect. Immun. 50:534-540.
17. Kreger, A. S., L. Dechatelet, and P. Shirley. 1984. Interaction of Vibrio vulnificus with human polymorphonuclear leukocytes: association of virulence with resistance to phagocytosis. J. Infect. Dis. 144:244-248.
18. Kreger, A. S., L. D. Gray, and J. Testa. 1984. Protection of mice against Vibrio vulnificus disease by vaccination with surface antigen preparations and anti-surface antigen antisera. Infect. Immun. 45:537-543.
19. Leroux-Roels, G., E. Moreau, B. Verhasselt, S. Biernaux, V. Brulien, M. Francotte, P. Pala, M. Slaopui, and P. Vandepapeliere. 1993. Immunogenicity and reactogenicity of a recombinant HSV-2 glycoprotein D vaccine with or without monophosphoryl lipid A in HSV seronegative and seropositive subjects, abstr. 1209, p. 341. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
20. Mitchell, M. S., J. Kan-Mitchell, R. A. Kempf, W. Harel, H. Shau, and S. Lind. 1988. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48:5883-5893.
21. Morris, J. G. 1988. Vibrio vulnificus - a new monster of the deep? Ann. Intern. Med. 109:261-263.
22. Morris, J. G., Jr., A. C. Wright, L. M. Simpson, P. K. Wood, D. E. Johnson, and J. D. Oliver. 1987. Virulence of Vibrio vulnificus: association with utilization of transferrin-bound iron, and lack of correlation with levels of cytotoxin or protcase production. FEMS Microbiol. Lett. 40:55-59.
23. Park, S. D., H. S. Shon, and N. J. Joh. 1991. Vibrio vulnificus septicemia in Korea: clinical and epidemiologic findings in seventy patients. J. Am. Acad. Dermatol. 24:397-403.
24. Pennington, J. E. 1990. Newer uses of intravenous immunoglobulins as anti-infective agents. Antimicrob. Agents Chemother. 34:1463-1466.
25. 24a. Powell, J. L., et al. Unpublished data.
26. Raza, H., and A. F. Cutrona. 1993. Vibrio vulnificus septicemia should prompt the search for liver disease. Infect. Dis. Clin. Pract. 2:273-274.
27. Reddy, G. P., U. Hayat, C. Abeygunawardana, C. Fox, A. C. Wright, B. R. Maneval, Jr., C. A. Bush, and J. G. Morris, Jr. 1992. Purification and determination of capsular polysaccharide of Vibrio vulnificus MO6-24. J. Bacteriol. 174:2620-2630.
28. Reddy, G. P., U. Hayat, C. A. Bush, and J. G. Morris, Jr. 1993. Capsular polysaccharide structure of a clinical isolate of Vibrio vulnificus strain BO62316 determined by heteronuclear NMR spectroscopy and high-performance anion-exchange chromatography. Anal. Biochem. 214:106-115.
29. Rickman, L. S., D. M. Gordon, R. Wistar, Jr., U. Krzych, M. Gross, M. R. Hollingdale, J. E. Egan, J. D. Chulay, and S. L. Hoffman. 1991. Use of an adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalene in malaria circumsporozoite protein vaccine. Lancet 337: 998-1001.
30. Shinoda, S., M. Kobayashi, H. Yamada, S. Yoshida, M. Ogawa, and Y. Mizuguchi. 1987. Inhibitory effect of capsular antigen of Vibrio vulnficus on bactericidal activity of human serum. Microbiol. Immunol. 31:393-401.
31. Siber, G. R., D. M. Ambrosino, J. McIver, T. J. Ervin, G. Schiffman, S. Sallan, and G. F. Grady. 1984. Preparation of human hyperimmune globulin to Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis. Infect. Immun. 45:248-254.
32. Simpson, L. M., V. K. While, S. F. Zane, and J. D. Oliver. 1987. Correlation between virulence and colony morphology in Vibrio vulnificus. Curr. Microbiol. 55:269-272.
33. Tacket, C. O., F. Brenner, and P. A. Blake. 1984. Clinical features and an epidemiologic study of Vibrio vulnificus infections. J. Infect. Dis. 149:558-561.
34. Takayama, K., N. Qureshi, E. Ribi, and J. L. Cantrell. 1984. Separation and characterization of toxic and non-toxic forms of lipid A. Rev. Infect. Dis. 6:439-443.
35. Thoelen, S., P. Van Damme, A. Meeus, F. Collard, M. Slaopui, and P. Vandepapeliere. 1993. Immunogenicity of a recombinant hepatitis B vaccine with monophosphoryl lipid A administered following various two dose schedules, abstr. 340, p. 182. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
36. U.S. Food and Drug Administration. 1993. To prevent Vibrio infections, high-risk patients should avoid eating raw molluscan shellfish. FDA Medical Bulletin 6 (March). U.S. Food and Drug Administration, Washington, D.C.
37. Whittman, C. M., and P. M. Griffin. 1993. Preventing Vibrio vulnificus infection in the high risk patient. Infect. Dis. Clin. Pract. 2:275-276.
38. Wright, A. C., and J. G. Morris, Jr. 1991. The extracellular cytolysin of Vibrio vulnificus: inactivation and relationship to virulence in mice. Infect. Immun. 59:192-197.
39. Wright, A. C., L. M. Simpson, J. D. Oliver, and J. G. Morris, Jr. 1990. Phenotypic evaluation of acapsular transposon mutants of Vibrio vulnificus. Infect. Immun. 58:1769-1773.
40. Yoshida, S. I., M. Ogawa, and Y. Mizuguchi. 1985. Relation of capsular materials and colony opacity to virulence of Vibrio vulnificus. Infect. Immun. 47:446-451.